Syndromic autism

This article may be too technical for most readers to understand. Please help improve it to make it understandable to non-experts, without removing the technical details. (June 2023) (Learn how and when to remove this template message)

Syndromic autism (or syndromic autism spectrum disorders) denotes cases of

. Cases without such association, which account for the majority of total autism cases, are known as non-syndromic autism (or non-syndromic autism spectrum disorders).

Studying the differences and similarities (e.g. common pathways) between syndromic and non-syndromic cases can provide insights about the pathophysiology of autism and pave the way to new autism therapies.^[1][2][3][4]

Syndromic autism

Autism spectrum disorder (ASD) is referred to as syndromic when it is one of the many characteristics associated with a broader

.

Syndromic autism represents about 25% of the total ASD cases.[4]^[5] In most^[quantify] cases, its etiology is known.^[2][4]

are one of the causes of syndromic autism, which in this case are also known as monogenic autism spectrum disorders. They account for about 5% of the total ASD cases.

Certain^[

]

Non-syndromic autism

Non-syndromic autism, also called classic autism or

idiopathic

autism (as in most cases, the etiology is unknown), represents the majority of total autism cases.

In most^[quantify] cases, its cause is polygenic.^{[citation needed]}

Classification

A 2017 study^[relevant?] proposed to replace the classification "syndromic"/"non-syndromic" ASD into one based on the genetic etiology of the condition, specifying if the syndromic condition occurs in the context of a "phenotype first" clinically defined syndrome or from a "genotype first" molecularly defined syndrome.^{[4][clarification needed]}

Following the proposal, ASD would be divided into three genetic categories:^[4]

Clinically defined

Syndromes recognized by clinicians (depending on their experience), typically confirmed by a targeted genetic testing.

• Chromosomal (e.g.: Down syndrome)
• Syndromes caused by mutations in single genes (e.g.:
  NF1, TSC, PTEN-associated macrocephaly syndrome, some males with FXS
  )
• Syndromes caused by CNVs (e.g.: microdeletion 22q11.2 syndrome)
• Teratogens (e.g.:
  valproate aembryopathy
  )

Molecularly defined

Syndromes recognized by genome-wide testing, not by hypothesis-driven testing (since clinical recognition is difficult).

• Chromosomal (e.g.: isodicentric 15q)
• ASD-risk genes (e.g.:
  ANK2, SCN2A
  )
• ASD-associated CNVs (e.g.: 16p11.2 deletion/duplication, exonic NRXN1 deletions)

Currently undefined

Currently undefined.^{[clarification needed]}

Characteristics of syndromic ASD conditions

Condition	Cause	Chromosome(s) involved (if a mutation)	ASD prevalence ( 95% CI )	Clinically/Molecularly defined	Other characteristics	Ref.
Fragile X syndrome	Monogenic disorder: FMR1 (encodes FMRP)	X	30% (20.0–31.0) [male individuals only]  22% (15.0–30.0) [mixed sex] 14% (13–18) [female individuals only]	Clinically defined [in some males]	Long/narrow face, hyperactivity, intellectual disability (ID), seizures	[1][3][4][6]
Rett syndrome	Monogenic disorder: MECP2	X	61.0% (46.0–74.0) [female individuals only]	Clinically defined	Microcephaly, breathing irregularities, language deficits, repetitive/stereotyped hand movements, epilepsy, ID	[1][3][4]
MECP2 duplication syndrome	Monogenic disorder: MECP2	X	100% [in a single study composed by 9 male participants]	Clinically defined	Brachycephaly, spasticity, recurrent respiratory infections, gastrointestinal hypermotility, genitourinary abnormalities, epilepsy, ID	[1][4][7]
Tuberous sclerosis complex	Monogenic disorder: TSC1 TSC2	9 16	36.0% (33.0–40.0)	Clinically defined	Benign tumours in multiple organs, epilepsy	[1][3][4]
Angelman's syndrome	Monogenic disorder: UBE3A	15	34.0% (24.0–37.0)		Cheerful demeanour, microcephaly, epilepsy, speech deficits, sleep disturbance, epilepsy, ID	[1][3]
Phelan-McDermid syndrome	Monogenic disorder: SHANK3	22	84% [in a single study composed by 32 participants]	Molecularly defined		[4][8]
Timothy syndrome	Monogenic disorder: CACNA1C	12	80% [in a single study composed by 17 participants]	Clinically defined		[4][9]
Smith-Lemli-Opitz syndrome	DHCR7	11	55% [in a single study composed by 33 participants]			[10]
Neurofibromatosis type I	NF1	17	18% (9.0–29.0)	Clinically defined		[3][4]
PTEN hamartoma tumor syndrome	Monogenic disorder: PTEN	10	17% (8–27)	Clinically defined		[4][11]
Down syndrome	Chromosomal disorder: trisomy 21	21	16% (8.0–24.0)	Clinically defined		[3][4]
Cohen's syndrome	Monogenic disorder: VPS13B	8	54% (44.0–64.0)	Clinically defined		[3][4]
Cornelia de Lange syndrome	Polygenic disorder		43% (32.0–53.0)	Clinically defined		[3][4]
CHARGE syndrome	Monogenic disorder: CHD7	8	28% (16–41)	Clinically defined		[4][12][13]
Noonan's syndrome	Polygenic disorder		15% (7.0–26.0)			[3]
William's syndrome	Microdeletion syndrome: 7q11.23	7	12% (6.0–20.0)			[3][14]
22q11.2 deletion syndrome	22q11.2	22	11% (5.0–19.0)	Clinically defined		[3][4]
Fetal valproate spectrum disorder	Teratogen: valproate		8–15% [in VPA exposed children]	Clinically defined		[4][15][16]

See also

• Causes of autism
• Conditions comorbid to autism spectrum disorders

References